2 Information about the treatments

Marketing authorisation indications

2.1

Nirmatrelvir plus ritonavir (Paxlovid, Pfizer) is 'indicated for the treatment of COVID‑19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID‑19'.

2.2

Sotrovimab (Xevudy, GlaxoSmithKline) is indicated 'for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute COVID‑19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection'.

2.3

Tocilizumab (RoActemra, Roche Products) is indicated 'for the treatment of coronavirus disease 2019 (COVID‑19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation'.

Dosage in the marketing authorisation

Price

2.7

The updated list price for nirmatrelvir plus ritonavir is confidential until released by the company and cannot be reported here.

2.8

The list price for sotrovimab is £2,209 per 500 mg/8 ml concentrate for solution for infusion vial (excluding VAT; BNF online, accessed October 2022). The company also has a commercial arrangement. This makes sotrovimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.9

The list price for tocilizumab is £256 per 200 mg/10 ml and £512 per 400 mg/20 ml concentrate for solution for infusion vial (excluding VAT; BNF online, accessed October 2022). The company of branded tocilizumab (RoActemra, Roche Products) has a commercial arrangement. This makes tocilizumab available to the NHS with a discount. The size of the discount is commercial in confidence. NHS England has completed a national procurement for tocilizumab, which includes the biosimilar versions of tocilizumab. Prices paid for the originator or biosimilar tocilizumab should be in line with the national procurement outcome and should be no higher than that provided through the original commercial arrangement.

  • National Institute for Health and Care Excellence (NICE)